Date: 2012-10-18
Type of information: Distribution agreement
Compound: Loramyc® (miconazole Lauriad™)
Company: BioAlliance Pharma (France) Shafayab Gostar (Iran)
Therapeutic area: Infectious diseases
Type agreement: distribution
commercialisation
Action mechanism:
Disease: oropharyngeal candidiasis in immunocompromised patients
Details: BioAlliance Pharma, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, has signed an agreement* with the Company Shafayab Gostar to distribute Loramyc® in Iran (miconazole Lauriad™ mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients).
Under this agreement, Shafayab Gostar is granted the right to import, promote and market Loramyc® in the Iranian territory once the registration procedures with the local authorities are completed. BioAlliance Pharma will remain the Marketing Authorization Holder of the product. This agreement was concluded through the Company Cytis AG.
Shafayab Gostar was established in 2001 and it represents Novartis, Bayer Schering, Boehringer Ingelheim, Eli Lilly, Hospira, Novo Nordisk, Nutricia, Actavis, OctaPharma, IBSA, Desitin and Convatec in Iran. Cytis AG is specialized in the commercialization and the promotion of drugs, medical devices and diagnostic products, especially in the Middle East.
Financial terms:
Latest news:
